A series of novel benzofuran-dihydropyridine hybrids were designed by molecular hybridization approach and evaluated for bone anabolic activities. Among the screened library, ethyl 4-(7-(sec-butyl)-2-(4-methylbenzoyl)benzofuran-5-yl)-2-methyl-5-oxo-1,4,5,6,7,8-hexahydroquinoline-3-carboxylate (compound 21) significantly enhanced the ALP production and mineralized nodule formation, which are primary requisites in the process of in vitro osteogenesis. Oral administration of compound 21 at 10 mg.kg⁻¹ day⁻¹ for two weeks led to restoration of trabecular bone microarchitecture in drill hole fracture model by significantly increasing BV/TV and Tb.N. Furthermore, histological and molecular studies showed compound 21 triggering the new bone regeneration in a drill hole defect site by increasing BMP expression. Furthermore, molecular modeling studies were performed to gain insight into the binding approach, which revealed that both benzofuran and dihydropyridine moieties are essential to show similar binding interactions to fit into the active site of BMP2 receptor, an important target of the osteogenic agents. Our results suggest that compound 21 stimulates BMP2 synthesis in osteoblast cells that promotes new bone formation (∼40%) at the fracture site which helps in shorten the healing period.

通过分子杂交方法设计了一系列新颖的苯并呋喃-二氢吡啶杂化物，并对其骨合成代谢活性进行了评估。在筛选的文库中，乙基4-（7-（仲丁基）-2-（4-甲基苯甲酰基）苯并呋喃-5-基）-2-甲基-5-氧代-1,4,5,6,7,8 -六氢喹啉-3-羧酸盐（化合物21）显着增强了ALP的产生和矿化的结节形成，这是体外成骨过程中的首要条件。以10 mg.kg ^-1 天^-1的剂量口服化合物21持续两周，可通过显着增加BV / TV和Tb.N来恢复钻孔骨折模型中的小梁骨微结构。此外，组织学和分子研究表明21通过增加BMP表达在钻孔缺损部位触发新的骨再生。此外，进行了分子建模研究以深入了解结合方法，该研究表明苯并呋喃和二氢吡啶部分对于显示相似的结合相互作用以适应成骨剂的重要靶点BMP2受体的活性位点都是必不可少的。我们的结果表明，化合物21刺激成骨细胞中BMP2的合成，从而促进骨折部位新骨的形成（约40％），从而有助于缩短愈合时间。